Navigation Links
Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting

logenous leukemia or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose- limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in unrelated cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs by arresting mitosis and cell proliferation without impacting unrelated, normal cellular functions, thereby avoiding many of the toxicities commonly experienced by patients treated with existing anti-mitotic drugs.

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' development efforts are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound, CK-182
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/31/2015)... 2015 Quietly, sedately, Morocco,s pharmaceutical ... domestic pharmaceutical industry is strong, with a well-developed base ... international standards. One place where the quality ... Africa: Morocco has quietly become the second largest African ... . Indeed, Moroccan pharma companies have been making ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... YORK, Oct. 6, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiry ... Impact Dyslipidemia Market Value ...
... NEW YORK, Oct. 6, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0254328/The-Future-of-European-Pharmaceutical-Distribution.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... to reduce internal costs for manufacturers, and ...
Cached Medicine Technology:Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 2Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 3Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 4Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 5Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 6Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 7Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 8Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 9Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 10Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 11Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 12Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 13Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 14Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 15The Future of European Pharmaceutical Distribution 2The Future of European Pharmaceutical Distribution 3The Future of European Pharmaceutical Distribution 4The Future of European Pharmaceutical Distribution 5The Future of European Pharmaceutical Distribution 6The Future of European Pharmaceutical Distribution 7The Future of European Pharmaceutical Distribution 8The Future of European Pharmaceutical Distribution 9
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed ... Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . ... migration of their Implanon® implants, inability to locate the implants, unsuccessful and invasive ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor ... out of the window, he recalled that his equipment was set up to depict the ... he jumped out of bed. , The photo speaks for itself. Chatfield is also a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels of ... study published today in Nature Communications and led by researchers from the Icahn School ... variations in the gene RTN1 led to greater production of the related RNT1 protein, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2
... Center have found a new technique that employs RNA, a ... lead to therapeutics// for conditions in which nudging a gene ... with a novel research tool to investigate the role that ... paper appearing online at Nature Chemical Biology and in an ...
... right type of fat may actually keep child obesity at ... unsaturated fat and very little omega-3. ,A study ... was undertaken by scientists at Goteborg University. These children belong ... revealed that 23% of the children belong to an overweight ...
... MPs, members of the Committee of Public Accounts, has come out ... ,Levels of obesity in children aged two to 10 years ... 2004, according to the Health Survey for England. , ... as obese. ,The Public Accounts Committee report ...
... Boston ranked the top city in America for having a ... conducted by Fit Pregnancy magazine, Boston’s outstanding// healthcare resources is ... like low birth risks and family recreation. The magazine shared ... Wednesday. ,Mayor Thomas M. Menino, while commenting on ...
... study finds that CT scans used in emergency rooms spotted ... MRI scans which are better in identifying any type of ... to magnetic resonance imaging,” wrote Dr. Geoffrey A. Donnan and ... note accompanying the study report. ,Doctors argue that ...
... project to revamp its healthcare infrastructure and train health ... expected to benefit over 45 million people. ,Health ... medical facilities at the village level and the project ... scheme would benefit over 45 million people at the ...
Cached Medicine News:Health News:A Novel Technique Nudges Genes Into Activity 2Health News:A Novel Technique Nudges Genes Into Activity 3Health News:Under-Elevens Hurtle Towards Obesity, British MPs Call for Action 2Health News:Mega Project to Revamp Karnataka’s Healthcar 2
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: